Answer
Caution is required because doravirine in Delstrigo may be a weak CYP3A inducer, while tacrolimus and sirolimus are sensitive CYP3A substrates with narrow therapeutic windows.
Sources for this answer
- Delstrigo 100 mg /300 mg /245 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 16Document updated
Sources checked